Therapeutic Risks Associated with Pharmaceutical Alternatives

Robert L. Day, John E. Murphy, J. Grady Strom, David B. Ludlum, Richard A. Levy

Research output: Contribution to journalLetter

1 Scopus citations

Abstract

To the Editor: In his letter in the September 19, 1985, issue,* Dr. Richard Levy discusses the potential for increased adverse effects and differences in drug blood levels if substitutions are made between pharmaceutical alternatives of the same chemical entity (i.e., tablets for syrups, one salt or ester of a drug for another, and so on). He cites 11 references, mentions no specific drugs, and concludes that “the risks associated with such substitution appear to outweigh any benefits that may accrue from this practice.” Since his references cover only five drugs (albuterol, erythromycin, levodopa, phenytoin, and theophylline), an electrolyte (potassium…

Original languageEnglish (US)
Number of pages1
JournalNew England Journal of Medicine
Volume315
Issue number13
DOIs
StatePublished - Sep 25 1986

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Therapeutic Risks Associated with Pharmaceutical Alternatives'. Together they form a unique fingerprint.

  • Cite this